A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Status:
Completed

Trial end date:
2001-06-01

Target enrollment:

Participant gender:

The purpose of this study is to investigate the safety and tolerability of multiple dose regimens of BIA 2-093 in healthy young male volunteers

Phase 1

Bial - Portela C S.A.

Eslicarbazepine acetate